We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





SARS-CoV-2 Acts as Sponge to Delete Specific Host microRNAs, Making it More Dangerous than Other Coronaviruses

By HospiMedica International staff writers
Posted on 24 Aug 2020
A team of researchers have proposed that the SARS-CoV-2 virus is more deadly than many other coronaviruses because the COVID-19 virus acts as a microRNA “sponge.” This action modulates host microRNA levels in ways that aid viral replication and stymies the host immune response.

Researchers from the University of Alabama at Birmingham (Birmingham, AL, USA) and Poland have proposed this testable hypothesis results based on their analysis of current literature and a bioinformatic study of the COVID-19 virus and six other coronaviruses.

Human microRNAs, or miRNAs, are short, non-coding RNAs with about 22 bases that act to regulate gene expression by their complementary pairing with specific messenger RNAs of the cell. More...
That pairing silences the messenger RNA, preventing it from being translated into a protein. Thus, miRNAs are a fine-tuned controller of cell metabolism or the cell’s response to stress and adverse challenges, like infection by a virus. The miRNAs are only about 0.01% of total human cell and tissue RNA, while replicating viral RNA of a virus like the COVID-19 virus may reach 50% of the total cellular RNA. Hence, the UAB and Polish researchers believe that if the COVID-19 virus has binding sites for specific miRNAs - and these sites are different from the binding sites for miRNAs found on coronaviruses that cause colds - the more pathogenic COVID-19 virus may selectively sponge up certain miRNAs to dysregulate the cell in ways that make it a dangerous human coronavirus. The two human coronaviruses prior to the COVID-19 virus - the severe acute respiratory coronavirus, or SARS virus, and the Middle East respiratory syndrome coronavirus, or MERS virus, - were both dangerous, but did not have the high infectivity of the SARS-CoV-2 virus, which causes COVID-19.

For their study, the researchers used computer-aided bioinformatic analysis to find potential miRNA target sites for 896 mature human miRNA sequences on seven different coronavirus genomes. These genomes included the three pathogenic coronaviruses - the SARS, MERS and COVID-19 viruses - and four non-pathogenic coronaviruses. The researchers found that the number of target sites was elevated in the pathogenic viruses compared to the non-pathogenic strains. Furthermore, they found that pathogenic human coronaviruses attracted sets of miRNAs that differ from the non-pathogenic human coronaviruses. In particular, a set of 28 miRNAs were unique for the COVID-19 virus; the SARS and MERS viruses had their own unique sets of 21 and 24 miRNAs, respectively.

Focusing on the 28 unique miRNAs for the COVID-19 virus, the researchers found that the majority of these miRNAs are well expressed in bronchial epithelial cells, and their dysregulation has been reported in human lung pathologies that include lung cancers, chronic obstructive pulmonary disease, cystic fibrosis and tuberculosis. Furthermore, many of the miRNAs have been proposed to act as tumor suppressors that target the pathways for programmed cell death, or apoptosis, that are supposed to make a cell kill itself when infected, mutated or stressed in other ways. Reduction of those miRNAs has been associated with poor cancer prognosis.

“Hence, the COVID-19 virus - by its potential reduction of the host’s miRNA pool - may promote infected cell survival and thus continuity of its replication cycle,” the researchers said.

Related Links:
University of Alabama at Birmingham


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.